These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10982197)

  • 21. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of tardive dyskinesia with donepezil: a pilot study.
    Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
    J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of tardive dyskinesia with vitamin E.
    Egan MF; Hyde TM; Albers GW; Elkashef A; Alexander RC; Reeve A; Blum A; Saenz RE; Wyatt RJ
    Am J Psychiatry; 1992 Jun; 149(6):773-7. PubMed ID: 1350428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin E in the treatment of tardive dyskinesia.
    Elkashef AM; Ruskin PE; Bacher N; Barrett D
    Am J Psychiatry; 1990 Apr; 147(4):505-6. PubMed ID: 1969247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
    Richardson MA; Bevans ML; Read LL; Chao HM; Clelland JD; Suckow RF; Maher TJ; Citrome L
    Am J Psychiatry; 2003 Jun; 160(6):1117-24. PubMed ID: 12777270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo.
    Sommer BR; Cohen BM; Satlin A; Cole JO; Jandorf L; Dorsey F
    J Geriatr Psychiatry Neurol; 1994; 7(4):234-7. PubMed ID: 7826493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.
    Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ
    Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial.
    Loonen AJ; Verwey HA; Roels PR; van Bavel LP; Doorschot CH
    J Clin Psychopharmacol; 1992 Feb; 12(1):39-42. PubMed ID: 1348061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
    Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
    J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baclofen in tardive dyskinesia patients maintained on neuroleptics.
    Stewart RM; Rollins J; Beckham B; Roffman M
    Clin Neuropharmacol; 1982 Dec; 5(4):365-73. PubMed ID: 6130838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.
    Bai YM; Yu SC; Chen JY; Lin CY; Chou P; Lin CC
    Int Clin Psychopharmacol; 2005 Mar; 20(2):79-85. PubMed ID: 15729082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics.
    Shenoy RS; Sadler AG; Goldberg SC; Hamer RM; Ross B
    J Clin Psychopharmacol; 1981 May; 1(3):141-5. PubMed ID: 6117584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.